The University of Michigan Hybridoma Core provides research services in custom monoclonal antibody development (mAb) and bulk production of monoclonal antibodies from established hybridomas (somatic cell hybrids). The Core has developed monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, purified proteins, hormones, hormone receptors and recombinant proteins and peptides. Services are available to all University of Michigan investigators as well as to other institutions and the private sector.
Our services include:
• Custom Monoclonal Antibody Development: immunization, serum collection, fusion and culture of selected hybridomas
• Subcloning of hybridomas: fusion clones selected in monoclonal antibody development or subcloning of existing mAb secreting hybridomas for stabilization or selection of clones with desired enhanced properties.
• Cryopreservation of Hybridomas and Hybridoma Repository (long term cryostorage: hybridomas generated in the Core or obtained from outside sources.
• Isotype Determination: from hybridoma culture supernatants
• Hybridomas from other sources: thawing and establishment in culture, cryopreservation, storage and all services listed here can be performed with any hybridoma(s) generated in laboratories or obtained from colleagues, the ATCC and other sources.
• Bulk monoclonal antibody production: in vivo production in mice, in vitro production in terminal cultures (small scale, 1-2 mg) or high density bioreactor cultures (large scale, 10-100 mg).
A custom monoclonal antibody development project begins with a no-fee consultation meeting with the Hybridoma Core Director and Manager, the laboratory Principle Investigator (or their designee) and all laboratory personnel who will be involved in the project. Strategies for antigen design, immunization and screening of animal sera and culture supernatants will be discussed in this meeting. Antibody development projects involve a partnership in which the Core performs all animal and cell culture procedures involved in the project and the laboratory provides antigen/immunogen preparations in a ready-to-inject, sterile form and carries out assays (e.g. ELISA, Flow cytometry) to screen provided hybridoma fusion culture supernatants for desired antibody activity, in a timely fashion.
Other services should be requested and arranged by contacting the Core.
The University of Michigan Hybridoma Core has been in continuous operation since its establishment in 1980 under the leadership of the Michigan Diabetes Research and Training Center. The Core is currently supported by recharges for the cost of services and is managed by the Internal Medicine Division of Rheumatology. We are committed to providing high quality, cost effective services from a well-trained staff to all of our researchers.
David Fox, MD | Director | ||
Elizabeth Smith | Assistant Director | 734-763-9271 | emsmith@med.umich.edu |
Hours | Location |
Monday - Friday 8:30AM - 5PM |
Room A562 MSRB II |
Name | Role | Phone | Location | |
---|---|---|---|---|
Elizabeth Smith |
Assistant Director/Core Manager
|
734 763-9271
|
hybridoma@umich.edu
|
A562 MSRB II
|